首页 > 最新文献

Annals of hepatology最新文献

英文 中文
P- 56 TUBERCULOSIS IN LIVER TRANSPLANT RECIPIENTS: EXPERIENCE OF A SINGLE CENTER P- 56 肝移植受者的结核病:单个中心的经验
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2023.101243
Cárdenas Ramírez Bertha , Padilla-Machaca P. Martin , Cerrón Cabezas Carmen

Introduction and Objectives

In Peru the tuberculosis (TB) is an endemic infectious disease. This disease is a serious opportunistic infection in transplant recipients (LTRs) and has 20 to 74-fold increase in a chance of developing compared to the general population The prevalence of TB in (LTRs) is variable between regions. This study aims to describe the rate, clinics characteristics and mortality of TB in LTRs from a high-prevalence area.

Materials and Methods

We conducted a retrospective review of liver transplant recipients with tuberculosis diagnoses at Guillermo Almenara Hospital between Mach 2001 and March 2022.

Results

A total of 294 patients underwent LT during this period. 7 (2.3 %) adult patients were diagnosed with active TB. Mean age was 49 (32- 64) years; 5 (70 %) were males. Time interval from LT to TB diagnosis was 57 months (2-136) and 42 % had early tuberculosis (< 12 m). Three patients had disseminated TB and Four pulmonary involvement. 72 % received individualized treatment to avoid hepatotoxicity related to treatment, 28.5% had DILI with standard treatment. We found 28.5 % mortality no related to TB infections.

Conclusions

We observed a low rate of TB in LTRs (2.3%) from a high prevalence region. Most of our patients received individualized treatment.

导言和目标在秘鲁,结核病(TB)是一种地方性传染病。肺结核是移植受者(LTRs)中的一种严重机会性感染,与普通人群相比,其发病几率增加了 20 到 74 倍。本研究旨在描述来自高发地区的肝移植受者中结核病的发病率、临床特征和死亡率。材料和方法我们对 2001 年马赫至 2022 年 3 月期间在吉列尔莫-阿尔梅纳拉医院确诊为结核病的肝移植受者进行了回顾性审查。7名(2.3%)成年患者被诊断为活动性肺结核。平均年龄为 49(32-64)岁;男性 5 人(70%)。从接受肺结核治疗到确诊肺结核的时间间隔为 57 个月(2-136),42% 的患者患有早期肺结核(12 个月)。三名患者为播散性肺结核,四名患者为肺部受累。72%的患者接受了个体化治疗,以避免与治疗相关的肝脏毒性,28.5%的患者在接受标准治疗后出现了肝脏损害。我们发现 28.5% 的死亡率与肺结核感染无关。我们的大多数患者都接受了个性化治疗。
{"title":"P- 56 TUBERCULOSIS IN LIVER TRANSPLANT RECIPIENTS: EXPERIENCE OF A SINGLE CENTER","authors":"Cárdenas Ramírez Bertha ,&nbsp;Padilla-Machaca P. Martin ,&nbsp;Cerrón Cabezas Carmen","doi":"10.1016/j.aohep.2023.101243","DOIUrl":"https://doi.org/10.1016/j.aohep.2023.101243","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>In Peru the tuberculosis (TB) is an endemic infectious disease. This disease is a serious opportunistic infection in transplant recipients (LTRs) and has 20 to 74-fold increase in a chance of developing compared to the general population The prevalence of TB in (LTRs) is variable between regions. This study aims to describe the rate, clinics characteristics and mortality of TB in LTRs from a high-prevalence area.</p></div><div><h3>Materials and Methods</h3><p>We conducted a retrospective review of liver transplant recipients with tuberculosis diagnoses at Guillermo Almenara Hospital between Mach 2001 and March 2022.</p></div><div><h3>Results</h3><p>A total of 294 patients underwent LT during this period. 7 (2.3 %) adult patients were diagnosed with active TB. Mean age was 49 (32- 64) years; 5 (70 %) were males. Time interval from LT to TB diagnosis was 57 months (2-136) and 42 % had early tuberculosis (&lt; 12 m). Three patients had disseminated TB and Four pulmonary involvement. 72 % received individualized treatment to avoid hepatotoxicity related to treatment, 28.5% had DILI with standard treatment. We found 28.5 % mortality no related to TB infections.</p></div><div><h3>Conclusions</h3><p>We observed a low rate of TB in LTRs (2.3%) from a high prevalence region. Most of our patients received individualized treatment.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101243"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268123003460/pdfft?md5=9236a87d717350831fefeed8fddcc801&pid=1-s2.0-S1665268123003460-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES O-1 布宜诺斯艾利斯省一家妇幼医院的孕妇乙型肝炎和丙型肝炎血清流行率及母婴传播情况
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2023.101251
Rosana Solis , Mabel Mora , María Julieta Venturini , Fernando Battiston , Guadalupe Masci , Adrián Zapata , Laura Abojer , Martina Ribeky , Mariana Turturicci , Laura Figueras , Margarita Barris , Alejandra Gaiano , Valeria Silenzi , Andrea Conesa , Gloria Capellini , Mayra Moyano , MANUEL MENDIZABAL

Introduction and Objectives

The WHO proposed to eliminate viral hepatitis by the year 2030. To achieve this ambitious goal, we must evaluate the seroprevalence of these infections in different populations. This study aimed to estimate the seroprevalence of hepatitis B (HBV) and C (HCV) among pregnant women and mother-to-child transmission in a maternal hospital.

Materials and Methods

We conducted an observational, prospective and consecutive study including pregnant women from San Isidro Maternal and Children Hospital whose births occurred between 05/01/2019 and 04/30/2021. In all patients HBsAg and anti-HCV were assessed during the 1st and 3rd trimester of pregnancy together with HIV. In the case of presenting HBsAg+, anti-HBcIgG was performed on the same sample followed by HBV-DNA PCR. In the case of presenting anti-HCV+, a confirmatory test was performed with PCR HCV-RNA. Neonates of HBsAg+ or HCV+ were follow-up for 3 years.

Results

2762 births were included during the period under study. Five (0.18%) HBsAg+ pregnant women were identified, median age was 25 years (range 17-36), of which only 1 had anti-HBcIgG+. Given the suspicion of chronic HBV and the delay in obtaining the HBV-DNA results, treatment with tenofovir was started. In successive controls, no chronic HBV infection was diagnosed in neonates. Anti-HCV+ was detected in 8 (0.29%) patients, with a median age of 29 years (range 19-38 years), of which only one patient presented detectable HCV-RNA, genotype 4. This patient had a diagnosis of HCV chronic prior to pregnancy and her son presented anti-HCV- at age 3. Finally, one patient with HBsAg+ and another with anti-HCV+, but negative viral loads presented HIV+.

Conclusions

The gestation period is an excellent opportunity to carry out health checks. During the studied period, the seroprevalence of HBsAg+ and anti-HCV+ was very low. These types of interventions are essential to achieve the objectives set by the WHO.

引言和目标世界卫生组织提出到 2030 年消除病毒性肝炎。为了实现这一宏伟目标,我们必须评估这些感染在不同人群中的血清流行率。本研究旨在估算一家妇产医院中孕妇的乙型肝炎(HBV)和丙型肝炎(HCV)血清流行率以及母婴传播情况。材料和方法我们开展了一项观察性、前瞻性和连续性研究,研究对象包括圣伊西德罗妇幼医院的孕妇,其分娩时间为 2019 年 1 月 5 日至 2021 年 1 月 4 日。所有患者均在妊娠期第一和第三季度接受了 HBsAg 和抗-HCV 以及 HIV 评估。如果出现 HBsAg+,则对同一样本进行抗 HBcIgG 检测,然后进行 HBV-DNA PCR 检测。如果出现抗-HCV+,则进行 PCR HCV-RNA 确认试验。对 HBsAg+ 或 HCV+ 的新生儿进行了为期 3 年的随访。发现 5 名(0.18%)HBsAg+ 孕妇,年龄中位数为 25 岁(17-36 岁),其中只有 1 名孕妇抗 HBcIgG+。鉴于怀疑存在慢性 HBV,且 HBV-DNA 检测结果迟迟未出,因此开始使用替诺福韦进行治疗。在连续的对照组中,没有新生儿被确诊为慢性 HBV 感染。8名患者(0.29%)检测出抗-HCV+,中位年龄为29岁(19-38岁),其中只有一名患者检测出HCV-RNA,基因型为4。这名患者在怀孕前被诊断出患有慢性 HCV,她的儿子在 3 岁时出现了抗 HCV-。最后,一名患者 HBsAg+,另一名患者抗 HCV+,但病毒载量阴性,HIV+。在研究期间,HBsAg+ 和抗-HCV+ 的血清阳性率非常低。这些类型的干预对于实现世界卫生组织设定的目标至关重要。
{"title":"O-1 SEROPREVALENCE AND MOTHER-TO-CHILD TRANSMISSION OF HEPATITIS B AND C VIRUSES AMONG PREGNANT WOMEN IN A MATERNAL AND CHILDREN HOSPITAL FROM THE PROVINCE OF BUENOS AIRES","authors":"Rosana Solis ,&nbsp;Mabel Mora ,&nbsp;María Julieta Venturini ,&nbsp;Fernando Battiston ,&nbsp;Guadalupe Masci ,&nbsp;Adrián Zapata ,&nbsp;Laura Abojer ,&nbsp;Martina Ribeky ,&nbsp;Mariana Turturicci ,&nbsp;Laura Figueras ,&nbsp;Margarita Barris ,&nbsp;Alejandra Gaiano ,&nbsp;Valeria Silenzi ,&nbsp;Andrea Conesa ,&nbsp;Gloria Capellini ,&nbsp;Mayra Moyano ,&nbsp;MANUEL MENDIZABAL","doi":"10.1016/j.aohep.2023.101251","DOIUrl":"https://doi.org/10.1016/j.aohep.2023.101251","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>The WHO proposed to eliminate viral hepatitis by the year 2030. To achieve this ambitious goal, we must evaluate the seroprevalence of these infections in different populations. This study aimed to estimate the seroprevalence of hepatitis B (HBV) and C (HCV) among pregnant women and mother-to-child transmission in a maternal hospital.</p></div><div><h3>Materials and Methods</h3><p>We conducted an observational, prospective and consecutive study including pregnant women from San Isidro Maternal and Children Hospital whose births occurred between 05/01/2019 and 04/30/2021. In all patients HBsAg and anti-HCV were assessed during the 1st and 3rd trimester of pregnancy together with HIV. In the case of presenting HBsAg+, anti-HBcIgG was performed on the same sample followed by HBV-DNA PCR. In the case of presenting anti-HCV+, a confirmatory test was performed with PCR HCV-RNA. Neonates of HBsAg+ or HCV+ were follow-up for 3 years.</p></div><div><h3>Results</h3><p>2762 births were included during the period under study. Five (0.18%) HBsAg+ pregnant women were identified, median age was 25 years (range 17-36), of which only 1 had anti-HBcIgG+. Given the suspicion of chronic HBV and the delay in obtaining the HBV-DNA results, treatment with tenofovir was started. In successive controls, no chronic HBV infection was diagnosed in neonates. Anti-HCV+ was detected in 8 (0.29%) patients, with a median age of 29 years (range 19-38 years), of which only one patient presented detectable HCV-RNA, genotype 4. This patient had a diagnosis of HCV chronic prior to pregnancy and her son presented anti-HCV- at age 3. Finally, one patient with HBsAg+ and another with anti-HCV+, but negative viral loads presented HIV+.</p></div><div><h3>Conclusions</h3><p>The gestation period is an excellent opportunity to carry out health checks. During the studied period, the seroprevalence of HBsAg+ and anti-HCV+ was very low. These types of interventions are essential to achieve the objectives set by the WHO.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101251"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S166526812300354X/pdfft?md5=54771d08a9df93dc710c1e0abc495df4&pid=1-s2.0-S166526812300354X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-5 APACHE STUDY DESIGN TO EVALUATE THE EFFICACY AND SAFETY OF PLASMA EXCHANGE WITH HUMAN SERUM ALBUMIN 5% ON SHORT-TERM SURVIVAL IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE AT HIGH RISK OF HOSPITAL MORTALITY. P-5 阿帕奇研究设计,旨在评估用 5%人血清白蛋白进行血浆置换对住院死亡风险较高的急慢性肝衰竭患者短期存活率的有效性和安全性。
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2023.101192
Nikolaos Pyrsopoulos , Giovanni Perricone , Jasmohan S. Bajaj , Thierry Gustot , Thomas Reiberger , Mireia Torres , Peter Nelson , Javier Fernandez , Apache Study Investigators

Introduction and Objectives

Acute-on-chronic liver failure (ACLF) in cirrhotic patients is characterized by acute deterioration of liver function and severe organ injury with high short-term mortality. Liver transplantation is the only treatment to improve survival. A pilot study suggested that plasma exchange with human serum albumin 5% (PEA5%) as a replacement fluid is feasible and safe in ACLF patients and may improve organ function and survival. This study aimed to assess PE-A5% as a treatment for patients with ACLF in a pivotal study.

Materials and Methods

A phase 3, multicenter, randomized (1:1), controlled, parallel-group, open-label study (APACHE) compares standard medical treatment (SMT) + PE-A5% (treatment arm) to SMT alone (control arm). PE-A5% is performed using Albutein 5% (Grifols). Treatment schedule consists of two initial PE-A5% sessions on consecutive days followed by every other day PE-A5% (min-max 4-9 PE-A5%). Patients receive IVIG (200mg/kg) after every 2 PE-A5% to prevent hypogammaglobulinemia-associated infections, and FFP after each PE-A5% to prevent coagulopathy. Eligible patients are adult (18-79 years old), with ACLF-1b, ACLF-2, or ACLF-3a at admission or during hospitalization. Main exclusion criteria are patients with ACLF-1a or ACLF-3b, ACLF >10 days before randomization, septic shock requiring norepinephrine (>0.3µg/kg/min) or a second vasopressor, active infection, and severe respiratory failure.

Results

Target enrollment is 380 ACLF patients at high risk of hospital mortality. The primary efficacy endpoint is the 90-day overall survival. Secondary efficacy endpoints include 90-day transplant-free survival and 28-day overall survival. Main exploratory endpoints include overall and transplant-free survival at days 28 and 90, in-patient hospital and ICU stay, incidence of organ failures and ACLF course. Safety analyses include adverse events, vital signs, physical assessments, and laboratory tests.

Conclusions

APACHE will provide pivotal results on the efficacy and safety of PE-A5% as a treatment to improve survival in ACLF (NCT03702920;EudraCT:2016-001787-10).

导言和目的肝硬化患者急性慢性肝功能衰竭(ACLF)的特点是肝功能急性恶化和严重的器官损伤,短期死亡率高。肝移植是提高存活率的唯一治疗方法。一项试点研究表明,用人血清白蛋白 5%(PEA5%)作为替代液进行血浆置换对 ACLF 患者是可行且安全的,并可改善器官功能和存活率。本研究旨在通过一项关键性研究评估 PE-A5% 作为 ACLF 患者的治疗方法。材料与方法一项第 3 期、多中心、随机(1:1)、对照、平行组、开放标签研究(APACHE)将标准药物治疗(SMT)+ PE-A5%(治疗组)与单纯 SMT(对照组)进行了比较。PE-A5% 采用 Albutein 5% (Grifols)。治疗计划包括连续两天的首次 PE-A5% 治疗,然后隔天进行一次 PE-A5%(最少-最多 4-9 次 PE-A5%)。患者在每两次 PE-A5% 后接受 IVIG(200 毫克/千克),以预防与低丙种球蛋白血症相关的感染,并在每次 PE-A5% 后接受 FFP,以预防凝血病。符合条件的患者为成人(18-79 岁),入院时或住院期间患有 ACLF-1b、ACLF-2 或 ACLF-3a。主要排除标准为:ACLF-1a或ACLF-3b患者、随机化前10天患有ACLF的患者、需要去甲肾上腺素(0.3µg/kg/min)或第二种血管抑制剂的脓毒性休克患者、活动性感染患者以及严重呼吸衰竭患者。主要疗效终点是 90 天总生存率。次要疗效终点包括 90 天无移植生存率和 28 天总生存率。主要探索性终点包括第28天和第90天的总生存率和无移植生存率、住院时间和重症监护室停留时间、器官功能衰竭发生率以及 ACLF 病程。安全性分析包括不良事件、生命体征、身体评估和实验室检查。结论APACHE将提供有关PE-A5%作为改善ACLF存活率的治疗方法的有效性和安全性的关键性结果(NCT03702920;EudraCT:2016-001787-10)。
{"title":"P-5 APACHE STUDY DESIGN TO EVALUATE THE EFFICACY AND SAFETY OF PLASMA EXCHANGE WITH HUMAN SERUM ALBUMIN 5% ON SHORT-TERM SURVIVAL IN PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE AT HIGH RISK OF HOSPITAL MORTALITY.","authors":"Nikolaos Pyrsopoulos ,&nbsp;Giovanni Perricone ,&nbsp;Jasmohan S. Bajaj ,&nbsp;Thierry Gustot ,&nbsp;Thomas Reiberger ,&nbsp;Mireia Torres ,&nbsp;Peter Nelson ,&nbsp;Javier Fernandez ,&nbsp;Apache Study Investigators","doi":"10.1016/j.aohep.2023.101192","DOIUrl":"https://doi.org/10.1016/j.aohep.2023.101192","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Acute-on-chronic liver failure (ACLF) in cirrhotic patients is characterized by acute deterioration of liver function and severe organ injury with high short-term mortality. Liver transplantation is the only treatment to improve survival. A pilot study suggested that plasma exchange with human serum albumin 5% (PEA5%) as a replacement fluid is feasible and safe in ACLF patients and may improve organ function and survival. This study aimed to assess PE-A5% as a treatment for patients with ACLF in a pivotal study.</p></div><div><h3>Materials and Methods</h3><p>A phase 3, multicenter, randomized (1:1), controlled, parallel-group, open-label study (APACHE) compares standard medical treatment (SMT) + PE-A5% (treatment arm) to SMT alone (control arm). PE-A5% is performed using Albutein 5% (Grifols). Treatment schedule consists of two initial PE-A5% sessions on consecutive days followed by every other day PE-A5% (min-max 4-9 PE-A5%). Patients receive IVIG (200mg/kg) after every 2 PE-A5% to prevent hypogammaglobulinemia-associated infections, and FFP after each PE-A5% to prevent coagulopathy. Eligible patients are adult (18-79 years old), with ACLF-1b, ACLF-2, or ACLF-3a at admission or during hospitalization. Main exclusion criteria are patients with ACLF-1a or ACLF-3b, ACLF &gt;10 days before randomization, septic shock requiring norepinephrine (&gt;0.3µg/kg/min) or a second vasopressor, active infection, and severe respiratory failure.</p></div><div><h3>Results</h3><p>Target enrollment is 380 ACLF patients at high risk of hospital mortality. The primary efficacy endpoint is the 90-day overall survival. Secondary efficacy endpoints include 90-day transplant-free survival and 28-day overall survival. Main exploratory endpoints include overall and transplant-free survival at days 28 and 90, in-patient hospital and ICU stay, incidence of organ failures and ACLF course. Safety analyses include adverse events, vital signs, physical assessments, and laboratory tests.</p></div><div><h3>Conclusions</h3><p>APACHE will provide pivotal results on the efficacy and safety of PE-A5% as a treatment to improve survival in ACLF (NCT03702920;EudraCT:2016-001787-10).</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101192"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268123002958/pdfft?md5=8d6962308fbc79301a93d2eb15e3d679&pid=1-s2.0-S1665268123002958-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
O-14 NON-ALCOHOLIC FATTY LIVER DISEASE IS INFLUENCED BY THE INTERACTION OF HELICOBACTER PYLORI INFECTION AND G-ALLELE OF PNPLA3 o-14 非酒精性脂肪肝受幽门螺杆菌感染和 pnpla3 的 g-等位基因相互作用的影响
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2023.101264
Facundo Maiorana , Magalí Neschuk , María Virginia Caronia , Adolfo Schneider , Georgina Veron , Pedro Dario Zapata , Fernando Javier Barreyro

Introduction and Objectives

The pathophysiology of NAFLD is only partially unrevealed; it is considered as a multifactorial disorder, attributed to multiple, parallel “hits,” both genetic and environmental. It has been described that the single nucleotide polymorphism at rs738409 in the PNPLA3 gene is strongly associated with hepatic steatosis and its progression. Conversely, H. pylori infection has been related to metabolic syndrome, type-2 diabetes mellitus, and dyslipidemia, which are known risk factors for NAFLD. However, the evaluation of Infection and the rs738409 polymorphism in the PNPLA3 gene has not been explored.

Materials and Methods

this is a preliminary report of a prospective multicenter study from December 2020 to June 2021 in northeastern Argentina. 76 dyspeptic adult patients who fulfilled the ROME-IV criteria and underwent gastroscopy, of which 69 were included. The presence of H. pylori was determined by gastric histology. Biochemical and clinical parameters were recorded. NAFLD was defined by liver ultrasonography. The PNPLA3 gene was analyzed by PCR-RFLP in rs738409.

Results

The prevalence of NAFLD was 45% (31/69), with Hpyl+ 48% (17/36) and Hpyl- 42% (14/33) (p: ns). The variables significantly associated with NAFLD were BMI, dyslipidemia, Diabetes/prediabetes, presence of the G allele of PNPLA3, and the GG genotype. In the multivariate analysis, BMI (OR 1.63 95%CI 1.22-2.19) and the G-allele of PNPLA3 (OR 7.35 95%CI 1.34-40) were independently associated with NAFLD. When subjects with NAFLD were analyzed, the interaction between Hpyl and PNPLA3 allele-G was significantly associated with NAFLD (65%) and increased risk of liver fibrosis (FIB-4 > 1.3 41%).

Conclusions

the presence of NAFLD was associated with BMI and G-allele of PNPLA3. The combination of Hpyl infection and the G-allele of PNPLA3 were associated with NAFLD and risk of fibrosis (FIB-4)

导言和目的:非酒精性脂肪肝的病理生理学尚未完全揭示;它被认为是一种多因素疾病,是由遗传和环境等多重并行 "打击 "造成的。有研究表明,PNPLA3 基因的单核苷酸多态性 rs738409 与肝脏脂肪变性及其进展密切相关。相反,幽门螺杆菌感染与代谢综合征、2 型糖尿病和血脂异常等非酒精性脂肪肝的已知危险因素有关。材料与方法这是 2020 年 12 月至 2021 年 6 月在阿根廷东北部进行的一项前瞻性多中心研究的初步报告。纳入了符合 ROME-IV 标准并接受胃镜检查的 76 名消化不良成人患者,其中 69 名患者接受了胃镜检查。通过胃组织学检查确定是否存在幽门螺杆菌。生化和临床参数均有记录。非酒精性脂肪肝是通过肝脏超声波检查确定的。通过 PCR-RFLP 分析了 PNPLA3 基因的 rs738409。结果非酒精性脂肪肝的患病率为 45%(31/69),其中 Hpyl+ 占 48%(17/36),Hpyl- 占 42%(14/33)(P:ns)。与非酒精性脂肪肝明显相关的变量有体重指数、血脂异常、糖尿病/再糖尿病、PNPLA3 的 G 等位基因和 GG 基因型。在多变量分析中,体重指数(OR 1.63 95%CI 1.22-2.19)和 PNPLA3 的 G 等位基因(OR 7.35 95%CI 1.34-40)与非酒精性脂肪肝独立相关。在对患有非酒精性脂肪肝的受试者进行分析时,Hpyl 和 PNPLA3 等位基因-G 之间的相互作用与非酒精性脂肪肝(65%)和肝纤维化风险增加(FIB-4 >;1.3 41%)显著相关。Hpyl感染和PNPLA3的G-等位基因组合与非酒精性脂肪肝和肝纤维化风险(FIB-4)相关。
{"title":"O-14 NON-ALCOHOLIC FATTY LIVER DISEASE IS INFLUENCED BY THE INTERACTION OF HELICOBACTER PYLORI INFECTION AND G-ALLELE OF PNPLA3","authors":"Facundo Maiorana ,&nbsp;Magalí Neschuk ,&nbsp;María Virginia Caronia ,&nbsp;Adolfo Schneider ,&nbsp;Georgina Veron ,&nbsp;Pedro Dario Zapata ,&nbsp;Fernando Javier Barreyro","doi":"10.1016/j.aohep.2023.101264","DOIUrl":"https://doi.org/10.1016/j.aohep.2023.101264","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>The pathophysiology of NAFLD is only partially unrevealed; it is considered as a multifactorial disorder, attributed to multiple, parallel “hits,” both genetic and environmental. It has been described that the single nucleotide polymorphism at rs738409 in the PNPLA3 gene is strongly associated with hepatic steatosis and its progression. Conversely, H. pylori infection has been related to metabolic syndrome, type-2 diabetes mellitus, and dyslipidemia, which are known risk factors for NAFLD. However, the evaluation of Infection and the rs738409 polymorphism in the PNPLA3 gene has not been explored.</p></div><div><h3>Materials and Methods</h3><p>this is a preliminary report of a prospective multicenter study from December 2020 to June 2021 in northeastern Argentina. 76 dyspeptic adult patients who fulfilled the ROME-IV criteria and underwent gastroscopy, of which 69 were included. The presence of H. pylori was determined by gastric histology. Biochemical and clinical parameters were recorded. NAFLD was defined by liver ultrasonography. The PNPLA3 gene was analyzed by PCR-RFLP in rs738409.</p></div><div><h3>Results</h3><p>The prevalence of NAFLD was 45% (31/69), with Hpyl+ 48% (17/36) and Hpyl- 42% (14/33) (p: ns). The variables significantly associated with NAFLD were BMI, dyslipidemia, Diabetes/prediabetes, presence of the G allele of PNPLA3, and the GG genotype. In the multivariate analysis, BMI (OR 1.63 95%CI 1.22-2.19) and the G-allele of PNPLA3 (OR 7.35 95%CI 1.34-40) were independently associated with NAFLD. When subjects with NAFLD were analyzed, the interaction between Hpyl and PNPLA3 allele-G was significantly associated with NAFLD (65%) and increased risk of liver fibrosis (FIB-4 &gt; 1.3 41%).</p></div><div><h3>Conclusions</h3><p>the presence of NAFLD was associated with BMI and G-allele of PNPLA3. The combination of Hpyl infection and the G-allele of PNPLA3 were associated with NAFLD and risk of fibrosis (FIB-4)</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101264"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268123003678/pdfft?md5=e55b6625ec6f2bcee1f43c8ba135d167&pid=1-s2.0-S1665268123003678-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
O-7 CURRENT PRACTICE OF LIVER TRANSPLANTATION IN LATIN AMERICAN COUNTRIES: AN ALEH INTEREST GROUP SURVEY 2023 O-7 拉丁美洲国家目前的肝移植实践:ALEH 兴趣小组调查 2023
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2023.101257
Paulo Bittencourt , Liana Codes , Adrian Gadano , Alejandra Villamil , Alfeu de Medeiros Fleck Jr , Álvaro Urzua , Debora Raquel Terrabuio , Eira Cerda , Graciela Elia Castro Narro , Ignacio Roca , John Abad González , Josefina Pages , Juan Carlos Restrepo Gutierrez , Leonardo de Lucca Schiavon , Mario Uribe , Martin Padilla , Norma Marlene Perez Figueroa , Pablo Coste Murillo , Raquel Stucchi , Ricardo Chong , Rodrigo Zapata

Introduction and Objectives

Little is known about current practice of liver transplantation (LT) in Latin American countries (LATAM). This study aimed to describe LT activity, immunosuppression protocols and policies regarding prophylaxis of cytomegalovirus (CMV) infection and hepatitis B virus (HBV) recurrence in different active LATAM centers.

Materials and Methods

A web-based survey with 20 questions regarding LT practice was sent to all members of ALEH LT SIG in December 2022.

Results

22 centers performing 35 [5-160] LT per year from Brazil (n=5), Argentina (n=4), Chile (n=4), Ecuador (n-2), Mexico (n=2), Colombia (n=1), Costa Rica (n=1), Peru (n=1), Dominican Republic (n=1) and Uruguay (n=1) answered the survey. Tacrolimus, mycophenolate and prednisone was the main immunosuppressive regimen employed by most (72%) centers and 81% of them referred basiliximab use for induction therapy in selected patients. Tailoring of immunosuppression was universally accepted, particularly in autoimmune hepatitis (AIH) (59%), hepatocellular carcinoma (54%) kidney dysfunction (77%) and primary biliary cirrhosis (33%). Weaning of corticosteroids at three, six and 12 months after LT was reported, respectively, by 41%, 36% and 23% of the centers, but policy for lifelong corticosteroid use in AIH-transplanted subjects was commonly observed (90%). Just four centers are currently performing protocol liver biopsies, while 18 of them are considering liver biopsy prior to steroid pulse therapy. HBIG and nucleos(t)ide analogs are used in most instances (73%) for HBV recurrence prevention, whereas CMV infection prophylaxis was shown to vary sharply across centers. Of note, all but two of them referred major changes in LT practice over the years due to economical restraints.

Conclusions

Compliance with standard of care recommendations for management of LT was reported by most centers. Heterogeneity in practices regarding HBV infection recurrence and CMV prophylaxis may reflect local financial restraints and point to the importance of developing ALEH guidelines to encourage LT activity in LATAM.

导言和目标目前,人们对拉丁美洲国家(LATAM)肝移植(LT)的实践知之甚少。本研究旨在描述拉美地区不同活跃中心的肝移植活动、免疫抑制方案以及巨细胞病毒(CMV)感染和乙型肝炎病毒(HBV)复发的预防政策。材料和方法2022年12月,向ALEH肝移植SIG的所有成员发送了一份网络调查,其中包含20个有关肝移植实践的问题。结果来自巴西(n=5)、阿根廷(n=4)、智利(n=4)、厄瓜多尔(n-2)、墨西哥(n=2)、哥伦比亚(n=1)、哥斯达黎加(n=1)、秘鲁(n=1)、多米尼加共和国(n=1)和乌拉圭(n=1)的22个每年进行35[5-160]次LT的中心回答了调查。他克莫司、霉酚酸酯和泼尼松是大多数中心(72%)采用的主要免疫抑制方案,其中 81% 的中心将巴利昔单抗用于选定患者的诱导治疗。定制免疫抑制方案被普遍接受,尤其是在自身免疫性肝炎(AIH)(59%)、肝细胞癌(54%)、肾功能不全(77%)和原发性胆汁性肝硬化(33%)中。41%、36%和23%的中心分别报告在LT术后3个月、6个月和12个月断用皮质类固醇,但AIH移植受试者终生使用皮质类固醇的政策很常见(90%)。目前仅有四家中心执行肝活检方案,而其中 18 家中心正在考虑在类固醇脉冲疗法前进行肝活检。在大多数情况下(73%),HBIG 和核苷(t)ide 类似物被用于预防 HBV 复发,而 CMV 感染的预防在各中心之间存在很大差异。值得注意的是,除两家中心外,其他所有中心都提到了多年来由于经济限制而在 LT 实践中发生的重大变化。关于HBV感染复发和CMV预防的不同做法可能反映了当地的经济限制,并表明了制定ALEH指南以鼓励拉丁美洲和加勒比海地区LT活动的重要性。
{"title":"O-7 CURRENT PRACTICE OF LIVER TRANSPLANTATION IN LATIN AMERICAN COUNTRIES: AN ALEH INTEREST GROUP SURVEY 2023","authors":"Paulo Bittencourt ,&nbsp;Liana Codes ,&nbsp;Adrian Gadano ,&nbsp;Alejandra Villamil ,&nbsp;Alfeu de Medeiros Fleck Jr ,&nbsp;Álvaro Urzua ,&nbsp;Debora Raquel Terrabuio ,&nbsp;Eira Cerda ,&nbsp;Graciela Elia Castro Narro ,&nbsp;Ignacio Roca ,&nbsp;John Abad González ,&nbsp;Josefina Pages ,&nbsp;Juan Carlos Restrepo Gutierrez ,&nbsp;Leonardo de Lucca Schiavon ,&nbsp;Mario Uribe ,&nbsp;Martin Padilla ,&nbsp;Norma Marlene Perez Figueroa ,&nbsp;Pablo Coste Murillo ,&nbsp;Raquel Stucchi ,&nbsp;Ricardo Chong ,&nbsp;Rodrigo Zapata","doi":"10.1016/j.aohep.2023.101257","DOIUrl":"https://doi.org/10.1016/j.aohep.2023.101257","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Little is known about current practice of liver transplantation (LT) in Latin American countries (LATAM). This study aimed to describe LT activity, immunosuppression protocols and policies regarding prophylaxis of cytomegalovirus (CMV) infection and hepatitis B virus (HBV) recurrence in different active LATAM centers.</p></div><div><h3>Materials and Methods</h3><p>A web-based survey with 20 questions regarding LT practice was sent to all members of ALEH LT SIG in December 2022.</p></div><div><h3>Results</h3><p>22 centers performing 35 [5-160] LT per year from Brazil (n=5), Argentina (n=4), Chile (n=4), Ecuador (n-2), Mexico (n=2), Colombia (n=1), Costa Rica (n=1), Peru (n=1), Dominican Republic (n=1) and Uruguay (n=1) answered the survey. Tacrolimus, mycophenolate and prednisone was the main immunosuppressive regimen employed by most (72%) centers and 81% of them referred basiliximab use for induction therapy in selected patients. Tailoring of immunosuppression was universally accepted, particularly in autoimmune hepatitis (AIH) (59%), hepatocellular carcinoma (54%) kidney dysfunction (77%) and primary biliary cirrhosis (33%). Weaning of corticosteroids at three, six and 12 months after LT was reported, respectively, by 41%, 36% and 23% of the centers, but policy for lifelong corticosteroid use in AIH-transplanted subjects was commonly observed (90%). Just four centers are currently performing protocol liver biopsies, while 18 of them are considering liver biopsy prior to steroid pulse therapy. HBIG and nucleos(t)ide analogs are used in most instances (73%) for HBV recurrence prevention, whereas CMV infection prophylaxis was shown to vary sharply across centers. Of note, all but two of them referred major changes in LT practice over the years due to economical restraints.</p></div><div><h3>Conclusions</h3><p>Compliance with standard of care recommendations for management of LT was reported by most centers. Heterogeneity in practices regarding HBV infection recurrence and CMV prophylaxis may reflect local financial restraints and point to the importance of developing ALEH guidelines to encourage LT activity in LATAM.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101257"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268123003605/pdfft?md5=06b19e255b799131e827c09eae2f0955&pid=1-s2.0-S1665268123003605-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
O- 8 PNPLA3 RS738409 C>G POLYMORPHISM IMPACT ON HCV-RELATED HCC DEVELOPMENT IN THE BRAZILIAN POPULATION: PRELIMINARY RESULTS O- 8 PNPLA3 rs738409 c>g 多态性对巴西人群中与 HCV 相关的 HCC 发展的影响:初步结果
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2023.101258
Claudia Maccali, Aline L Chagas, Lisa Rc Saud, Regiane Ssm Alencar, Michele Sg Gouvea, Joyce Mks Etto, Isabel V Pereira, Arthur In Oliveira, Jose T Stefano, Rafael Sn Pinheiro, Wellington Andraus, Paulo Herman, Luiz Ac D'albuquerque, Mario G Pessoa, Claudia P Oliveira

Introduction and Objectives

The PNPLA3 rs738409 C>G polymorphism has been associated with hepatocellular carcinoma (HCC) and liver cirrhosis regardless of the etiology, although the association was stronger with non-viral etiologies. However, the influence of PNPLA3 polymorphism on Hepatitis C Virus (HCV) and whether this polymorphism could be a risk factor for HCV-related HCC is not well defined. We aimed to evaluate the influence of the PNPLA3 rs738409 C>G polymorphism on the risk of HCC occurrence in HCV patients in Brazil.

Materials and Methods

This study included 90 patients with HCV-related cirrhosis and HCC who underwent liver transplantation or resection at a tertiary center in Brazil and 111 patients non-HCC with HCV-related cirrhosis, as the control group. The rs738409 polymorphism was detected in the DNA extracted from patients' blood samples using the TaqMan assay. All clinical data were collected using the Research Electronic Data Capture (REDCap) tool. The statistical analyses were performed using Jamovi software version 2.3.23.

Results

In the HCV+HCC group there was a higher proportion of male gender (79.1% vs. 45.9%, p<0.001), history of alcoholism (80.5% vs. 22.5%, p<0.001) and smoking (68.9% vs. 25.2%, p<0.001), however there was no statistical difference in age (p=0.519) and BMI (p=0.403) between both groups. The genotype frequencies of the rs738409 polymorphism in the HCV+HCC group was CC 41,2% CC and CG/GG 58,8% vs. controls CC 49,5% and CG/GG 50,5%. The presence of the G allele was not an independent factor associated with the risk of HCC occurrence (r=0,199, p=0.53).

Conclusions

Even in an admixed population such as the Brazilian, there was no association between the PNPLA3 rs738409 C>G polymorphism and the risk of developing HCV-related HCC, as previously shown in published studies in caucasian and oriental population.

引言和目的PNPLA3 rs738409 C>G多态性与肝细胞癌(HCC)和肝硬化相关,与病因无关,但与非病毒性病因的相关性更强。然而,PNPLA3 多态性对丙型肝炎病毒(HCV)的影响以及该多态性是否会成为与 HCV 相关的 HCC 的风险因素,目前还没有明确的定义。我们的目的是评估 PNPLA3 rs738409 C>G 多态性对巴西 HCV 患者 HCC 发生风险的影响。材料与方法本研究纳入了 90 名在巴西一家三级中心接受肝移植或切除术的 HCV 相关肝硬化和 HCC 患者,以及 111 名非 HCV 相关肝硬化的 HCC 患者作为对照组。研究人员使用 TaqMan 法检测了从患者血液样本中提取的 DNA 中的 rs738409 多态性。所有临床数据均通过研究电子数据采集(REDCap)工具收集。统计分析使用 Jamovi 软件 2.3.23 版进行。结果在 HCV+HCC 组中,男性(79.1% 对 45.9%,p<0.001)、酗酒史(80.5% 对 22.5%,p<0.001)和吸烟史(68.9% 对 25.2%,p<0.001)的比例较高,但两组患者在年龄(p=0.519)和体重指数(p=0.403)方面没有统计学差异。HCV+HCC组的rs738409多态性基因型频率为CC 41.2%、CC和CG/GG 58.8%,对照组为CC 49.5%、CG/GG 50.5%。结论即使在巴西这样的混血人群中,PNPLA3 rs738409 C>G多态性与罹患HCV相关HCC的风险之间也没有关联,这与之前在白种人和东方人中已发表的研究结果一致。
{"title":"O- 8 PNPLA3 RS738409 C>G POLYMORPHISM IMPACT ON HCV-RELATED HCC DEVELOPMENT IN THE BRAZILIAN POPULATION: PRELIMINARY RESULTS","authors":"Claudia Maccali,&nbsp;Aline L Chagas,&nbsp;Lisa Rc Saud,&nbsp;Regiane Ssm Alencar,&nbsp;Michele Sg Gouvea,&nbsp;Joyce Mks Etto,&nbsp;Isabel V Pereira,&nbsp;Arthur In Oliveira,&nbsp;Jose T Stefano,&nbsp;Rafael Sn Pinheiro,&nbsp;Wellington Andraus,&nbsp;Paulo Herman,&nbsp;Luiz Ac D'albuquerque,&nbsp;Mario G Pessoa,&nbsp;Claudia P Oliveira","doi":"10.1016/j.aohep.2023.101258","DOIUrl":"https://doi.org/10.1016/j.aohep.2023.101258","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>The PNPLA3 rs738409 C&gt;G polymorphism has been associated with hepatocellular carcinoma (HCC) and liver cirrhosis regardless of the etiology, although the association was stronger with non-viral etiologies. However, the influence of PNPLA3 polymorphism on Hepatitis C Virus (HCV) and whether this polymorphism could be a risk factor for HCV-related HCC is not well defined. We aimed to evaluate the influence of the PNPLA3 rs738409 C&gt;G polymorphism on the risk of HCC occurrence in HCV patients in Brazil.</p></div><div><h3>Materials and Methods</h3><p>This study included 90 patients with HCV-related cirrhosis and HCC who underwent liver transplantation or resection at a tertiary center in Brazil and 111 patients non-HCC with HCV-related cirrhosis, as the control group. The rs738409 polymorphism was detected in the DNA extracted from patients' blood samples using the TaqMan assay. All clinical data were collected using the Research Electronic Data Capture (REDCap) tool. The statistical analyses were performed using Jamovi software version 2.3.23.</p></div><div><h3>Results</h3><p>In the HCV+HCC group there was a higher proportion of male gender (79.1% vs. 45.9%, p&lt;0.001), history of alcoholism (80.5% vs. 22.5%, p&lt;0.001) and smoking (68.9% vs. 25.2%, p&lt;0.001), however there was no statistical difference in age (p=0.519) and BMI (p=0.403) between both groups. The genotype frequencies of the rs738409 polymorphism in the HCV+HCC group was CC 41,2% CC and CG/GG 58,8% vs. controls CC 49,5% and CG/GG 50,5%. The presence of the G allele was not an independent factor associated with the risk of HCC occurrence (r=0,199, p=0.53).</p></div><div><h3>Conclusions</h3><p>Even in an admixed population such as the Brazilian, there was no association between the PNPLA3 rs738409 C&gt;G polymorphism and the risk of developing HCV-related HCC, as previously shown in published studies in caucasian and oriental population.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101258"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268123003617/pdfft?md5=fa14c2415f76f336d699585f220f749e&pid=1-s2.0-S1665268123003617-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BUN/creatinine ratio associated with mortality in patients with cirrhosis and acute kidney injury. 与肝硬化和急性肾损伤患者死亡率相关的尿素氮/肌酐比值。
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2024.101439
Diego F. Abendaño-Rivera , Cristian Y Sánchez-Sánchez , Karina Cazarin-Chávez , Paloma M. Diego-Salazar , Daniel Santana-Vargas , María F. Higuera-De La Tijera , José L. Pérez-Hernández

Introduction and Objectives

Cirrhosis is a prevalent disease worldwide, with complications such as acute kidney injury (AKI) that increase the risk of fatal outcomes. A high BUN/creatinine ratio (IBC) has been associated with mortality in other diseases Therefore, evaluating this index in patients with cirrhosis could predict mortality. To determine whether a high BUN/creatinine ratio is associated with mortality in patients with cirrhosis and AKI.

Materials and Patients

Retrospective analysis was conducted on a cohort of cirrhotic patients with and without AKI, calculating the IBC and assessing its association with mortality.

Results

A total of 201 patients with cirrhosis were included, of whom 106 were male (52.73%), with a mean age of 55±10.4 years. The distribution of Child Pugh scores was as follows: A (25, 12.43%), B (70, 34.82%), and C (106, 52.73%); the mean MELD-Na score was 21.8±9.45. The cumulative mortality rate at 28 days was 37 (18.4%) and at 90 days was 39 (24.4%). The model was not significant at 28 days but was significant at 90 days with a X2 value of 48.18 (2) and p<0.001.

At 90 days, the model was significant with a x2 value of 49.7 (2) and p<0.001, with an OR (IBC) of 2.78 (1.08-7.11, 95% CI, p=0.33), and for AKI OR of 7.97 (2.2-28.8, 95% CI, p=0.02) (Figure 1). Considering either factor present, the model was significant at 28 days with a X2 of 27.75 (1) and p<0.001, with an OR of 7.2 (3-17.3, p<0.001), and at 90 days with a X2 of 35.59 (1) and p<0.001, with an OR of 6.67 (3.23-13.76, p<0.001).

Conclusions

The Cox proportional hazards model was used to compare factors associated with mortality separately for AKI (present vs. absent) and IBC (>20 mg/dl vs. <20 mg/dl) at 28 and 90 days, as well as if both factors were present. The model was considered significant if the p-value was less than 0.5. The study concluded that a higher IBC (>20 mg/dl) could predict mortality in patients with cirrhosis, as the odds ratios at 28 and 90 days were significant.

导言和目的肝硬化是一种世界性流行疾病,其并发症如急性肾损伤(AKI)会增加致命风险。因此,评估肝硬化患者的这一指标可以预测死亡率。材料和患者对一组有和无 AKI 的肝硬化患者进行了回顾性分析,计算 IBC 并评估其与死亡率的关系。结果共纳入 201 例肝硬化患者,其中 106 例为男性(52.73%),平均年龄为 55±10.4 岁。儿童普氏评分分布如下:A(25,12.43%)、B(70,34.82%)和C(106,52.73%);平均 MELD-Na 评分为 21.8±9.45。28 天的累积死亡率为 37(18.4%),90 天的累积死亡率为 39(24.4%)。该模型在28天时不显著,但在90天时显著,X2值为48.18(2),p<0.001。在90天时,该模型显著,X2值为49.7(2),p<0.001,OR(IBC)为2.78(1.08-7.11,95% CI,p=0.33),AKI OR为7.97(2.2-28.8,95% CI,p=0.02)(图1)。考虑到任一因素的存在,模型在28天时显著,X2为27.75(1),p<0.001,OR为7.2(3-17.3,p<0.001);在90天时显著,X2为35.59(1),p<0.001,OR为6.67(3.23-13.76,p<0.001).结论Cox比例危险模型用于分别比较AKI(存在 vs. 不存在)和IBC(>20 mg/dl vs. <20mg/dl)在28天和90天的死亡率相关因素,以及同时存在这两个因素时的死亡率相关因素。如果 p 值小于 0.5,则认为该模型有意义。研究认为,较高的 IBC(20 毫克/分升)可预测肝硬化患者的死亡率,因为 28 天和 90 天的几率比较大。
{"title":"BUN/creatinine ratio associated with mortality in patients with cirrhosis and acute kidney injury.","authors":"Diego F. Abendaño-Rivera ,&nbsp;Cristian Y Sánchez-Sánchez ,&nbsp;Karina Cazarin-Chávez ,&nbsp;Paloma M. Diego-Salazar ,&nbsp;Daniel Santana-Vargas ,&nbsp;María F. Higuera-De La Tijera ,&nbsp;José L. Pérez-Hernández","doi":"10.1016/j.aohep.2024.101439","DOIUrl":"https://doi.org/10.1016/j.aohep.2024.101439","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Cirrhosis is a prevalent disease worldwide, with complications such as acute kidney injury (AKI) that increase the risk of fatal outcomes. A high BUN/creatinine ratio (IBC) has been associated with mortality in other diseases Therefore, evaluating this index in patients with cirrhosis could predict mortality. To determine whether a high BUN/creatinine ratio is associated with mortality in patients with cirrhosis and AKI.</p></div><div><h3>Materials and Patients</h3><p>Retrospective analysis was conducted on a cohort of cirrhotic patients with and without AKI, calculating the IBC and assessing its association with mortality.</p></div><div><h3>Results</h3><p>A total of 201 patients with cirrhosis were included, of whom 106 were male (52.73%), with a mean age of 55±10.4 years. The distribution of Child Pugh scores was as follows: A (25, 12.43%), B (70, 34.82%), and C (106, 52.73%); the mean MELD-Na score was 21.8±9.45. The cumulative mortality rate at 28 days was 37 (18.4%) and at 90 days was 39 (24.4%). The model was not significant at 28 days but was significant at 90 days with a X2 value of 48.18 (2) and p&lt;0.001.</p><p>At 90 days, the model was significant with a x2 value of 49.7 (2) and p&lt;0.001, with an OR (IBC) of 2.78 (1.08-7.11, 95% CI, p=0.33), and for AKI OR of 7.97 (2.2-28.8, 95% CI, p=0.02) (Figure 1). Considering either factor present, the model was significant at 28 days with a X2 of 27.75 (1) and p&lt;0.001, with an OR of 7.2 (3-17.3, p&lt;0.001), and at 90 days with a X2 of 35.59 (1) and p&lt;0.001, with an OR of 6.67 (3.23-13.76, p&lt;0.001).</p></div><div><h3>Conclusions</h3><p>The Cox proportional hazards model was used to compare factors associated with mortality separately for AKI (present vs. absent) and IBC (&gt;20 mg/dl vs. &lt;20 mg/dl) at 28 and 90 days, as well as if both factors were present. The model was considered significant if the p-value was less than 0.5. The study concluded that a higher IBC (&gt;20 mg/dl) could predict mortality in patients with cirrhosis, as the odds ratios at 28 and 90 days were significant.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101439"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002333/pdfft?md5=acaeabb67acde1713fe510a88ffb1c28&pid=1-s2.0-S1665268124002333-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140066641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of intravenous L-ornithine L-aspartate in patients with grade III and IV hepatic encephalopathy 静脉注射 L-鸟氨酸-L-天门冬氨酸对 III 级和 IV 级肝性脑病患者的疗效和安全性
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2024.101441
Gabriela Rangel-Zavala, Laura V. Cupil- Escobedo, María F. Higuera-de la Tijera, José L. Pérez-Hernandez

Introduction and Objectives

Hepatic encephalopathy (HE) is a common and serious complication of cirrhosis, associated with high morbidity and mortality. Ammonia and inflammation are the main triggers of HE. The use of L-ornithine-L-aspartate (LOLA) provides precursor substances for glutamine synthesis in perivenous cells, accelerating ammonia detoxification.

This study aims to evaluate the efficacy and safety of intravenous L-ornithine-L-aspartate (LOLA) in patients with grade III-IV hepatic encephalopathy (HE).

Materials and Patients

Retrospective and analytical study of patients with grade III-IV hepatic encephalopathy (HE).

All patients received intravenous LOLA 50 g for up to 48 hours, excluding those with renal failure. Descriptive statistics with measures of central tendency and dispersion were performed. Improvement was considered when HE regressed by at least one grade, and adverse events were evaluated.

Results

A total of 32 patients were included, with a mean age of 55 years ± 9.6. There were 13 females (40.6%) and 19 males (59.4%). Eight patients (25%) were classified as Child-Pugh B, while 24 patients (75%) were classified as Child-Pugh C. The mean MELD score was 19.03 ± 6.08, and the mean MELD NA score was 7.19 ± 7.19. The most common etiology was alcohol-related (43.8%), followed by MAFLD (29.1%) and viral (9.5%). All patients had grade III hepatic encephalopathy. The precipitating factors were sepsis (53%), hemorrhage (25%), constipation (12.5%), diuretics (6.3%), and electrolyte imbalance (3.1%). A total of 24 patients (75%) responded to the treatment, while 8 patients (25%) did not. Nineteen patients were found to have some degree of acute-on-chronic liver failure (ACLF). No adverse events were reported.

Conclusions

The use of intravenous LOLA for the treatment of grade III-IV hepatic encephalopathy iseffective and safe. These results support the use of LOLA as a therapeutic option in the management of hepatic encephalopathy in this patient population.

导言和目的肝性脑病(HE)是肝硬化常见的严重并发症,发病率和死亡率都很高。氨和炎症是肝性脑病的主要诱因。本研究旨在评估静脉注射 L-鸟氨酸-L-天门冬氨酸(LOLA)对 III-IV 级肝性脑病(HE)患者的疗效和安全性。材料和患者对 III-IV 级肝性脑病(HE)患者进行的回顾性分析研究。所有患者均接受 50 克 LOLA 静脉注射,最长 48 小时,不包括肾功能衰竭患者。研究采用了描述性统计方法,对中心倾向和离散程度进行了测量。如果 HE 至少下降了一个等级,则认为病情有所好转,并对不良反应进行评估。其中女性 13 人(40.6%),男性 19 人(59.4%)。8 名患者(25%)被归类为 Child-Pugh B,24 名患者(75%)被归类为 Child-Pugh C。最常见的病因与酒精有关(43.8%),其次是MAFLD(29.1%)和病毒(9.5%)。所有患者都患有 III 级肝性脑病。诱发因素包括败血症(53%)、出血(25%)、便秘(12.5%)、利尿剂(6.3%)和电解质失衡(3.1%)。共有 24 名患者(75%)对治疗有反应,8 名患者(25%)没有反应。19名患者出现了某种程度的急性-慢性肝功能衰竭(ACLF)。结论使用静脉注射 LOLA 治疗 III-IV 级肝性脑病既有效又安全。这些结果支持将 LOLA 作为治疗肝性脑病的一种选择。
{"title":"Efficacy and safety of intravenous L-ornithine L-aspartate in patients with grade III and IV hepatic encephalopathy","authors":"Gabriela Rangel-Zavala,&nbsp;Laura V. Cupil- Escobedo,&nbsp;María F. Higuera-de la Tijera,&nbsp;José L. Pérez-Hernandez","doi":"10.1016/j.aohep.2024.101441","DOIUrl":"https://doi.org/10.1016/j.aohep.2024.101441","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Hepatic encephalopathy (HE) is a common and serious complication of cirrhosis, associated with high morbidity and mortality. Ammonia and inflammation are the main triggers of HE. The use of L-ornithine-L-aspartate (LOLA) provides precursor substances for glutamine synthesis in perivenous cells, accelerating ammonia detoxification.</p><p>This study aims to evaluate the efficacy and safety of intravenous L-ornithine-L-aspartate (LOLA) in patients with grade III-IV hepatic encephalopathy (HE).</p></div><div><h3>Materials and Patients</h3><p>Retrospective and analytical study of patients with grade III-IV hepatic encephalopathy (HE).</p><p>All patients received intravenous LOLA 50 g for up to 48 hours, excluding those with renal failure. Descriptive statistics with measures of central tendency and dispersion were performed. Improvement was considered when HE regressed by at least one grade, and adverse events were evaluated.</p></div><div><h3>Results</h3><p>A total of 32 patients were included, with a mean age of 55 years ± 9.6. There were 13 females (40.6%) and 19 males (59.4%). Eight patients (25%) were classified as Child-Pugh B, while 24 patients (75%) were classified as Child-Pugh C. The mean MELD score was 19.03 ± 6.08, and the mean MELD NA score was 7.19 ± 7.19. The most common etiology was alcohol-related (43.8%), followed by MAFLD (29.1%) and viral (9.5%). All patients had grade III hepatic encephalopathy. The precipitating factors were sepsis (53%), hemorrhage (25%), constipation (12.5%), diuretics (6.3%), and electrolyte imbalance (3.1%). A total of 24 patients (75%) responded to the treatment, while 8 patients (25%) did not. Nineteen patients were found to have some degree of acute-on-chronic liver failure (ACLF). No adverse events were reported.</p></div><div><h3>Conclusions</h3><p>The use of intravenous LOLA for the treatment of grade III-IV hepatic encephalopathy iseffective and safe. These results support the use of LOLA as a therapeutic option in the management of hepatic encephalopathy in this patient population.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101441"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002357/pdfft?md5=83754b95fb2f8f3a976562147ea144ea&pid=1-s2.0-S1665268124002357-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140066643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the hepatoprotective effect of Flourensia cernua against the damage induced ischemia-reperfusion in Wistar rats. 评估苁蓉对 Wistar 大鼠缺血再灌注损伤的保肝作用
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2024.101417
Evelyn L. García-Carmona , Ramiro Tijerina-Márquez , Liliana Torres-González , Diana Moreno-Peña , Diana R. Rodríguez-Rodríguez , Paulina Espíndola-Vela , Linda E. Muñoz-Espinosa , Edelmiro Pérez-Rodríguez , Homero Zapata-Chavira , Paula Cordero-Pérez

Introduction and Objectives

Liver transplantation is the optimal treatment in patients with irreversible liver damage. The principal complication of a transplant is ischemia-reperfusion injury (I/R), which induces primary graft rejection. Treatment with plant extracts prior to I/R has decreased the severity of this injury due to their potential anti-inflammatory and antioxidant activity. A plant that presents potential antioxidant activity is Flourensia cernua (Fc). The objective was to evaluate the hepatoprotective effect of Flourensia cernua against the damage induced by ischemia-reperfusion in Wistar rats.

Materials an Patients

42 mixed Wistar rats were sorted into 7 groups (n=6). Fc was administered (200 mg/kg/, p.o/5 days) followed by I/R clamping of the left portal triad producing 1hr of 70% ischemia and 2 or 24hrs of reperfusion. Biochemical and oxidative stress biomarkers, proinflammatory cytokine and gene expression were determined. Ethics Committee approval under HI17-00002 registry and PAICYT 152-CS-2022 financing. The research group declares no conflict of interest.

Results

The I/R groups with 2 (IR2hr) and 24 hour (IR24hr) reperfusion displayed significantly elevated ALT and AST concentrations vs. Sham (SH); only FcIR2hr significantly decreased these enzymes (Figure 1). The remaining biochemical parameters did not show any significant differences between the groups. IR2hr group induced a statistically significant alteration of oxidative stress biomarkers, Fc counteracted these effects, with a decrease of malondialdehyde(MDA) and an increase of reduced glutathione (GSH) and the superoxide dismutase(SOD) (Figure 2). The gene expression of NFκβ was increased in IR2hr group, the treatment with F. cernua counteracted this increase. TNF-α was significantly increased in the IR2hr group and decreased in the treatment group.

Conclusions

I/R is a widely studied injury model, capable of inducing pathological changes in several spheres, not unlike the observed results in the present study; the hydroalcoholic extract of Fc displayed anti-inflammatory and antioxidant activity at 200mg/kg, it was not toxic and proved to be hepatoprotective against I/R.

导言和目的肝移植是治疗不可逆性肝损伤患者的最佳方法。移植的主要并发症是缺血再灌注损伤(I/R),它会诱发原发性移植排斥反应。由于植物提取物具有潜在的抗炎和抗氧化活性,因此在 I/R 前使用植物提取物治疗可降低这种损伤的严重程度。一种具有潜在抗氧化活性的植物是Flourensia cernua(Fc)。研究目的是评估 Fc 对 Wistar 大鼠缺血再灌注引起的肝损伤的保护作用。给大鼠注射 Fc(200 mg/kg/,p.o/5 天),然后夹闭左侧门静脉三联体,造成 1 小时 70% 的缺血和 2 或 24 小时的再灌注。测定生化和氧化应激生物标志物、促炎细胞因子和基因表达。伦理委员会批准了 HI17-00002 登记和 PAICYT 152-CS-2022 资助。研究小组声明无利益冲突。结果与 Sham(SH)相比,再灌注 2 小时(IR2hr)和 24 小时(IR24hr)的 I/R 组显示 ALT 和 AST 浓度显著升高;只有 FcIR2hr 能显著降低这些酶(图 1)。其余的生化指标在各组之间没有任何明显差异。IR2hr 组诱导氧化应激生物标志物发生了统计学意义上的显著变化,而 Fc 则抵消了这些影响,降低了丙二醛(MDA),增加了还原型谷胱甘肽(GSH)和超氧化物歧化酶(SOD)(图 2)。在 IR2hr 组中,NFκβ 的基因表达增加,而 F. cernua 可以抵消这种增加。结论I/R是一种被广泛研究的损伤模型,能够诱导多个领域的病理变化,与本研究中观察到的结果并不相同;Fc的水醇提取物在200毫克/千克时显示出抗炎和抗氧化活性,它没有毒性,并被证明对I/R具有肝保护作用。
{"title":"Evaluation of the hepatoprotective effect of Flourensia cernua against the damage induced ischemia-reperfusion in Wistar rats.","authors":"Evelyn L. García-Carmona ,&nbsp;Ramiro Tijerina-Márquez ,&nbsp;Liliana Torres-González ,&nbsp;Diana Moreno-Peña ,&nbsp;Diana R. Rodríguez-Rodríguez ,&nbsp;Paulina Espíndola-Vela ,&nbsp;Linda E. Muñoz-Espinosa ,&nbsp;Edelmiro Pérez-Rodríguez ,&nbsp;Homero Zapata-Chavira ,&nbsp;Paula Cordero-Pérez","doi":"10.1016/j.aohep.2024.101417","DOIUrl":"https://doi.org/10.1016/j.aohep.2024.101417","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Liver transplantation is the optimal treatment in patients with irreversible liver damage. The principal complication of a transplant is ischemia-reperfusion injury (I/R), which induces primary graft rejection. Treatment with plant extracts prior to I/R has decreased the severity of this injury due to their potential anti-inflammatory and antioxidant activity. A plant that presents potential antioxidant activity is <em>Flourensia cernua</em> (Fc). The objective was to evaluate the hepatoprotective effect of <em>Flourensia cernua</em> against the damage induced by ischemia-reperfusion in Wistar rats.</p></div><div><h3>Materials an Patients</h3><p>42 mixed Wistar rats were sorted into 7 groups (n=6). Fc was administered (200 mg/kg/, p.o/5 days) followed by I/R clamping of the left portal triad producing 1hr of 70% ischemia and 2 or 24hrs of reperfusion. Biochemical and oxidative stress biomarkers, proinflammatory cytokine and gene expression were determined. Ethics Committee approval under HI17-00002 registry and PAICYT 152-CS-2022 financing. The research group declares no conflict of interest.</p></div><div><h3>Results</h3><p>The I/R groups with 2 (IR2hr) and 24 hour (IR24hr) reperfusion displayed significantly elevated ALT and AST concentrations vs. Sham (SH); only FcIR2hr significantly decreased these enzymes (Figure 1). The remaining biochemical parameters did not show any significant differences between the groups. IR2hr group induced a statistically significant alteration of oxidative stress biomarkers, Fc counteracted these effects, with a decrease of malondialdehyde(MDA) and an increase of reduced glutathione (GSH) and the superoxide dismutase(SOD) (Figure 2). The gene expression of NFκβ was increased in IR2hr group, the treatment with <em>F. cernua</em> counteracted this increase. TNF-α was significantly increased in the IR2hr group and decreased in the treatment group.</p></div><div><h3>Conclusions</h3><p>I/R is a widely studied injury model, capable of inducing pathological changes in several spheres, not unlike the observed results in the present study; the hydroalcoholic extract of Fc displayed anti-inflammatory and antioxidant activity at 200mg/kg, it was not toxic and proved to be hepatoprotective against I/R.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101417"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002114/pdfft?md5=121c531cc34ee204076505a0327abeb7&pid=1-s2.0-S1665268124002114-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140066736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Immunoglobulin G against Hepatitis A Virus and Hepatitis E Virus in healthcare personnel 医护人员甲型肝炎病毒和戊型肝炎病毒免疫球蛋白 G 的流行率
IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-01 DOI: 10.1016/j.aohep.2024.101461
Jorge A. Garay-Ortega, Aleida Bautista-Santos, Rosalba Moreno-Alcántar

Introduction and Objectives

The hepatitis A and hepatitis E viruses are organisms that stand out for their high resistance to acid and alkaline media, as well as to freezing temperatures. Despite presenting an approximate mortality of 1% for both viruses, a seroprevalence of up to 81.3% has been reported in previous decades, so it is important to know the current epidemiological status of both diseases.

Materials and Patients

Cross-sectional, descriptive, prospective and observational study. Individuals over 18 years of age were recruited, who were studying or had the degree of gastroenterologists at the Hospital de Especialidades Centro Médico Nacional Siglo XXI, in a period of time between June 01 and June 30, 2023. Blood samples were collected for detection of immunoglobulin G against hepatitis A and hepatitis E viruses and a demographic questionnaire was conducted to each of the participants.

Results

23 individuals were recruited, 60.9% men (n=14) and 39.1% women (n=9), with a median age of 29 years, 13.0% corresponding to individuals from Mexico City (n= 3) and 86.9% from other states of the Mexican Republic (n=20). A seroprevalence of 17.3% (n=4) and 4.3% (n=1) was reported for hepatitis A virus and hepatitis E virus, respectively.

Conclusions

There is a lower seroprevalence for hepatitis A and hepatitis E viruses than reported, so it is vitally important to take preventive measures in populations at risk of infection, such as health personnel.

引言和目的甲型肝炎病毒和戊型肝炎病毒是一种对酸性和碱性介质以及低温具有高度抵抗力的生物。尽管这两种病毒的死亡率约为 1%,但据报道,在过去几十年中,这两种病毒的血清流行率高达 81.3%,因此了解这两种疾病的流行现状非常重要。研究人员招募了 18 岁以上、在 2023 年 6 月 1 日至 6 月 30 日期间在国家二十一世纪医学中心医院(Hospital de Especialidades Centro Médico Nacional Siglo XXI)学习或拥有肠胃病学学位的人。结果共招募了 23 人,其中男性占 60.9%(14 人),女性占 39.1%(9 人),年龄中位数为 29 岁,13.0% 的人来自墨西哥城(3 人),86.9% 的人来自墨西哥共和国其他州(20 人)。甲型肝炎病毒和戊型肝炎病毒的血清流行率分别为 17.3%(4 人)和 4.3%(1 人)。结论甲型肝炎病毒和戊型肝炎病毒的血清流行率比报告的要低,因此在医务人员等高危人群中采取预防措施至关重要。
{"title":"Prevalence of Immunoglobulin G against Hepatitis A Virus and Hepatitis E Virus in healthcare personnel","authors":"Jorge A. Garay-Ortega,&nbsp;Aleida Bautista-Santos,&nbsp;Rosalba Moreno-Alcántar","doi":"10.1016/j.aohep.2024.101461","DOIUrl":"https://doi.org/10.1016/j.aohep.2024.101461","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>The hepatitis A and hepatitis E viruses are organisms that stand out for their high resistance to acid and alkaline media, as well as to freezing temperatures. Despite presenting an approximate mortality of 1% for both viruses, a seroprevalence of up to 81.3% has been reported in previous decades, so it is important to know the current epidemiological status of both diseases.</p></div><div><h3>Materials and Patients</h3><p>Cross-sectional, descriptive, prospective and observational study. Individuals over 18 years of age were recruited, who were studying or had the degree of gastroenterologists at the Hospital de Especialidades Centro Médico Nacional Siglo XXI, in a period of time between June 01 and June 30, 2023. Blood samples were collected for detection of immunoglobulin G against hepatitis A and hepatitis E viruses and a demographic questionnaire was conducted to each of the participants.</p></div><div><h3>Results</h3><p>23 individuals were recruited, 60.9% men (n=14) and 39.1% women (n=9), with a median age of 29 years, 13.0% corresponding to individuals from Mexico City (n= 3) and 86.9% from other states of the Mexican Republic (n=20). A seroprevalence of 17.3% (n=4) and 4.3% (n=1) was reported for hepatitis A virus and hepatitis E virus, respectively.</p></div><div><h3>Conclusions</h3><p>There is a lower seroprevalence for hepatitis A and hepatitis E viruses than reported, so it is vitally important to take preventive measures in populations at risk of infection, such as health personnel.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101461"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002552/pdfft?md5=e3a2fb72b87600e4cfed33bb78da4a24&pid=1-s2.0-S1665268124002552-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140066757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1